Initial Public Offering
Sequana Medical
Joint Global Coordinator and Joint BookrunnerKempen acted as Joint Global Coordinator and Joint Bookrunner in the successful €27.5 million initial public offering of Sequana Medical
Transaction highlights
- Initial public offering on Euronext Brussels of 3,235,294 primary shares at a price of €8.50 per share
- Gross proceeds will be used to support the execution of the Company’s strategy, in particular the North American pivotal study on the alfapump® for the treatment of liver recurrent and refractory ascites, the European commercial roll-out, and other clinical development programmes
- Kempen extensively marketed the transaction towards specialist and generalist institutional investors during investor education (PDIE) and bookbuilding
- In addition, Van Lanschot Private banking marketed the transaction to their clients in Belgium
- The orderbook has been built with strong local support from high-quality long-term institutional investors as well as a mix of long-term, specialist and generalist investors across Europe; the transaction furthermore attracted strong support from Belgian retail investors which, in line with Belgian law, were allocated c. 10% of the IPO
- Trading of Sequana Medical's shares on the regulated market of Euronext Brussels under the symbol "SEQUA" commenced on 11 February 2019
- Sequana Medical’s IPO marks the second European Life Sciences initial public offering in 2019 and the third successful Kempen Life Sciences ECM transaction this year
Company description
Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical's lead product alfapump® is a fully implantable, programmable, wirelessly-charged, battery-powered system that is CE-marked for the management of i) refractory ascites (chronic fluid build-up in the abdomen) due to liver cirrhosis and ii) malignant ascites (with a life expectancy of six months or less). The company recently received Breakthrough Device designation from the FDA for its alfapump® for the treatment of liver recurrent or refractory ascites. The number of patients with liver refractory ascites is forecasted to increase dramatically due to the growing prevalence of NASH (Non-alcoholic Steatohepatitis). Sequana Medical is developing the alfapump® DSR, built upon the proven alfapump® platform, to deliver a convenient and fully implanted system for Direct Sodium Removal ("DSR") therapy, a novel and proprietary approach for the management of volume overload in heart failure. A first in human study for DSR therapy is ongoing. Sequana Medical is headquartered in Ghent, Belgium.
Contact
Lees meer over:
Transactions
No transactions found
Accelerated Bookbuild Offering
Capital increase
Global offering
US public offering
Rights issue
Initial Public Offering
Initial Public Offering on NASDAQ
Secondary placing of Fagron shares
Rights issue
a subsidiary of
Sale of German DIY portfolio to REDOS acting on behalf of Union Investment
Accelerated bookbuild offering
Accelerated Bookbuild Offering on behalf of selling shareholders in
Three-day bookbuild offering
Rights issue
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Initial Public Offering
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
Block trade in Boskalis shares
US public offering
US public offering
Sale to
US public offering
Sale of Rabo Bouwfonds CIF datacenter portfolio to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Public offer for
Accelerated bookbuild offering
Fundraise
Rights issue Public offer by German listed ADLER Real Estate
for Israeli listed
Public offer by German Vonovia
Accelerated bookbuild offering
Sale of Dynamic Portfolios
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Accelerated bookbuild offering
Sale of 3 German residential portfolios by
to consortium of buyers
US public offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Public offer by
for
Public takeover by German Vonovia
For Austrian Conwert
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Management participation advisory in dual-track sale process
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Accelerated bookbuild and private placement
Rights issue
